CA2220182C - Method of altering the contents of eggs - Google Patents
Method of altering the contents of eggs Download PDFInfo
- Publication number
- CA2220182C CA2220182C CA002220182A CA2220182A CA2220182C CA 2220182 C CA2220182 C CA 2220182C CA 002220182 A CA002220182 A CA 002220182A CA 2220182 A CA2220182 A CA 2220182A CA 2220182 C CA2220182 C CA 2220182C
- Authority
- CA
- Canada
- Prior art keywords
- egg
- dopa
- eggs
- effective amount
- laying animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000013601 eggs Nutrition 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title claims abstract description 40
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 122
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 67
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 55
- 241001465754 Metazoa Species 0.000 claims abstract description 34
- 244000144977 poultry Species 0.000 claims abstract description 32
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 25
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 19
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 19
- 235000013305 food Nutrition 0.000 claims abstract description 3
- 230000017448 oviposition Effects 0.000 claims description 18
- 230000037396 body weight Effects 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 claims description 5
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims description 5
- 229960000911 benserazide Drugs 0.000 claims description 5
- 229960004205 carbidopa Drugs 0.000 claims description 5
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 5
- DGMPVYSXXIOGJY-UHFFFAOYSA-N Fusaric acid Chemical compound CCCCC1=CC=C(C(O)=O)N=C1 DGMPVYSXXIOGJY-UHFFFAOYSA-N 0.000 claims description 4
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 3
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 229960002563 disulfiram Drugs 0.000 claims description 2
- 229960003151 mercaptamine Drugs 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 claims 4
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 claims 2
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 claims 1
- 229960000903 pantethine Drugs 0.000 claims 1
- 235000008975 pantethine Nutrition 0.000 claims 1
- 239000011581 pantethine Substances 0.000 claims 1
- 230000001965 increasing effect Effects 0.000 abstract description 13
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 238000010348 incorporation Methods 0.000 abstract 1
- 229940107161 cholesterol Drugs 0.000 description 54
- 235000013594 poultry meat Nutrition 0.000 description 28
- 230000009467 reduction Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 235000019624 protein content Nutrition 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 11
- 235000019625 fat content Nutrition 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 230000037213 diet Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 7
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 235000021003 saturated fats Nutrition 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000021081 unsaturated fats Nutrition 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 230000003028 elevating effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 2
- 229960002604 colestipol Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- DKCPKDPYUFEZCP-UHFFFAOYSA-N 2,6-di-tert-butylphenol Chemical compound CC(C)(C)C1=CC=CC(C(C)(C)C)=C1O DKCPKDPYUFEZCP-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 102000030904 bile acid binding Human genes 0.000 description 1
- 108091022863 bile acid binding Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000014107 unsaturated dietary fats Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L15/00—Egg products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/455,390 US5665375A (en) | 1995-05-31 | 1995-05-31 | Method of altering the contents of eggs |
| US08/455,390 | 1995-05-31 | ||
| PCT/US1996/007742 WO1996038132A1 (en) | 1995-05-31 | 1996-05-22 | Method of altering the contents of eggs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2220182A1 CA2220182A1 (en) | 1996-12-05 |
| CA2220182C true CA2220182C (en) | 2001-12-18 |
Family
ID=23808605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002220182A Expired - Fee Related CA2220182C (en) | 1995-05-31 | 1996-05-22 | Method of altering the contents of eggs |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US5665375A (OSRAM) |
| EP (1) | EP0836474A1 (OSRAM) |
| JP (1) | JP2912931B2 (OSRAM) |
| CN (1) | CN1185734A (OSRAM) |
| AU (1) | AU715383B2 (OSRAM) |
| CA (1) | CA2220182C (OSRAM) |
| WO (1) | WO1996038132A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999022725A1 (en) * | 1997-10-31 | 1999-05-14 | Cyncron Corporation | Method for modifying the growth rate, feed efficiency and body composition of domestic animals |
| US7413759B2 (en) * | 1998-05-21 | 2008-08-19 | Beech-Nut Nutrition Corporation | Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions |
| US6579551B1 (en) | 1998-05-21 | 2003-06-17 | Beech-Nut Nutrition Corporation | Baby-food compositions containing egg yolk and methods therefor |
| US7141266B2 (en) * | 1998-05-21 | 2006-11-28 | Beech-Nut Nutrition Corporation | Baby-food compositions enhancing visual acuity and methods therefor |
| US6149964A (en) * | 1998-05-21 | 2000-11-21 | Beech-Nut Nutrition Corporation | Egg yolk-containing baby food compositions and methods therefor |
| US6509375B1 (en) | 1999-01-14 | 2003-01-21 | Cyncron Corporation | Method for increasing productivity in breeder hens |
| US6316041B1 (en) | 1999-10-26 | 2001-11-13 | Liferight Foods, L.L.C. | Poultry egg with beneficial health and nutritive values |
| US6630181B1 (en) | 2000-09-20 | 2003-10-07 | Dupont Specialty Grains | Method of reducing cholesterol and altering fatty acid content of eggs |
| GB2377874B (en) * | 2001-07-23 | 2005-06-22 | Walcom Bio Chemicals Ind Ltd | Poultry feed and the use thereof |
| GB2379854B (en) * | 2001-09-19 | 2006-04-19 | Walcom Animal Science | Dairy cow feed and the use thereof |
| GB2386817B (en) * | 2002-02-20 | 2006-08-23 | Walcom Animal Science | Feed for fish and use therof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1518726A (en) * | 1975-11-04 | 1978-07-26 | Sankyo Co | Method of enhancing reproductive efficiency in nonhuman animals |
| US4241082A (en) * | 1977-09-02 | 1980-12-23 | Sankyo Company Limited | Agents for promoting reproductive ability of domestic animals |
| US5091195A (en) * | 1989-07-24 | 1992-02-25 | Havens Alice L | System for producing low cholesterol eggs and feed additive resulting in same |
| HUT63327A (en) * | 1990-06-13 | 1993-08-30 | Univ Louisiana State | Process for producing pharmaceutical composition comprising l-dihydroxylphenyl alanine (l-dopa), suitable for activating reproduction of seasonally reproducible animals |
| US5106836A (en) * | 1991-02-22 | 1992-04-21 | Clintec Nutrition Co. | Enteral diet |
| CN1046080C (zh) * | 1995-05-05 | 1999-11-03 | 郭永年 | 一种家禽饲料添加剂及其制备方法 |
-
1995
- 1995-05-31 US US08/455,390 patent/US5665375A/en not_active Expired - Lifetime
-
1996
- 1996-05-22 JP JP8536585A patent/JP2912931B2/ja not_active Expired - Lifetime
- 1996-05-22 CN CN96194296A patent/CN1185734A/zh active Pending
- 1996-05-22 AU AU58786/96A patent/AU715383B2/en not_active Ceased
- 1996-05-22 CA CA002220182A patent/CA2220182C/en not_active Expired - Fee Related
- 1996-05-22 WO PCT/US1996/007742 patent/WO1996038132A1/en not_active Ceased
- 1996-05-22 EP EP96920507A patent/EP0836474A1/en not_active Ceased
- 1996-12-30 US US08/777,463 patent/US5759567A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0836474A1 (en) | 1998-04-22 |
| JP2912931B2 (ja) | 1999-06-28 |
| US5759567A (en) | 1998-06-02 |
| JPH10508758A (ja) | 1998-09-02 |
| CN1185734A (zh) | 1998-06-24 |
| AU5878696A (en) | 1996-12-18 |
| CA2220182A1 (en) | 1996-12-05 |
| AU715383B2 (en) | 2000-02-03 |
| WO1996038132A1 (en) | 1996-12-05 |
| EP0836474A4 (OSRAM) | 1998-05-27 |
| US5665375A (en) | 1997-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU752217B2 (en) | Process and product for promoting weight loss in overweight dogs | |
| AU744814B2 (en) | A method for increasing incorporation efficiency of omega-3 highly unsaturated fatty acid in poultry meat | |
| CA2220182C (en) | Method of altering the contents of eggs | |
| AU771921B2 (en) | Method for selectively altering body fat level, feed efficiency, or weight gain | |
| JPH03219838A (ja) | 体脂肪の蓄積量を減少させる飼料 | |
| KR20010000198A (ko) | 옻사료의 제조 및 이를 급이 사육한 옻닭과 옻란의생산방법. | |
| CN1138821A (zh) | 提高有益动物抗紧张能力和免疫力的饲料和饮用水添加剂 | |
| CN1169659A (zh) | 用于养殖鱼的饲料、提供高品质鱼肉的方法以及用于制备所述饲料的附加组分的用途 | |
| AU2017408659B2 (en) | Animal feed with beta adrenergic agonist and isoquinoline alkaloid | |
| KR100490698B1 (ko) | 콜레스테롤 저하용 사료첨가제 및 이를 급여하여 생산된 계란 또는 돈육 | |
| RU2826308C1 (ru) | Способ повышения продуктивности цыплят-бройлеров путём снижения оксидативного стресса | |
| SI22407A (sl) | Uporaba koencima q10 za uäśinkovitejĺ o vzrejo ĺ˝ivali in pridelavo ĺ˝ivalskih tkiv s poveäśano vsebnostjo tega koencima | |
| US6509375B1 (en) | Method for increasing productivity in breeder hens | |
| RU2229876C2 (ru) | Способ выращивания телят | |
| EP1641475B1 (en) | Lipids from methanotrophic bacteria for cholesterol reduction | |
| Rahmawati et al. | Effect of Guanidinoacetic Acid in Feed with Different Protein Levels on the Performance and Internal Organ Characteristics of Broiler Chickens | |
| Rahmawati et al. | on the Performance and Internal Organ | |
| Qasim et al. | Effect of Adding Dietary Conjugated Linoleic Acid to Broiler Diets on Production Performance and Fatty Acid Content in Meat | |
| WO1999022725A1 (en) | Method for modifying the growth rate, feed efficiency and body composition of domestic animals | |
| KR20030030409A (ko) | 계육내 타우린 성분 함유량 극대화 방법 | |
| KR20040027191A (ko) | 콜레스테롤이 감소된 알(卵)의 생산방법 | |
| Langarodi et al. | Effect of Protexin (probiotic) and formic acid on performance of broilers. | |
| Lohakare | 6 The effects of vitamin C-polyethylene glycol complex on growth performance and immunity in broiler chickens | |
| WO2003063610A1 (en) | Oil including omega-3 fatty acids with therapeutic properties | |
| WO2003045162A1 (en) | Method of fattening poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |